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Link Between Increased Satiety Gut Hormones and
Reduced Food Reward After Gastric Bypass Surgery
for Obesity
Anthony P. Goldstone,* Alexander D. Miras,* Samantha Scholtz, Sabrina Jackson,
Karl J. Neff, Luc Pénicaud, Justin Geoghegan, Navpreet Chhina, Giuliana Durighel,
Jimmy D. Bell, Sophie Meillon,* and Carel W. le Roux*†
Context:Roux-en-Ygastric bypass (RYGB) surgery is an effective long-term intervention forweight
loss maintenance, reducing appetite, and also food reward, via unclear mechanisms.
Objective: To investigate the role of elevated satiety gut hormones after RYGB,we examined food
hedonic-reward responses after their acute post-prandial suppression.
Design: These were randomized, placebo-controlled, double-blind, crossover experimental med-
icine studies.
Patients: Two groups, more than 5 months after RYGB for obesity (n  7–11), compared with
nonobese controls (n 10), or patients after gastric banding (BAND) surgery (n 9) participated
in the studies.
Intervention: Studies were performed after acute administration of the somatostatin analog oc-
treotide or saline. In one study, patients after RYGB, and nonobese controls, performed a behav-
ioralprogressive ratio task for chocolate sweets. Inanother study,patientsafterRYGB,andcontrols
after BAND surgery, performed a functional magnetic resonance imaging food picture evaluation
task.
Main Outcome Measures: Octreotide increased both appetitive food reward (breakpoint) in the
progressive ratio task (n  9), and food appeal (n  9) and reward system blood oxygen level-
dependent signal (n 7) in the functional magnetic resonance imaging task, in the RYGB group,
but not in the control groups.
Results: Octreotide suppressed postprandial plasma peptide YY, glucagon-like peptide-1, and
fibroblast growth factor-19 after RYGB. The reduction in plasma peptide YY with octreotide pos-
itively correlatedwith the increase in brain reward system blood oxygen level-dependent signal in
RYGB/BAND subjects, with a similar trend for glucagon-like peptide-1.
Conclusions: Enhanced satiety gut hormone responses after RYGB may be a causative mechanism
by which anatomical alterations of the gut in obesity surgery modify behavioral and brain reward
responses to food. (J Clin Endocrinol Metab 101: 599–609, 2016)
Roux-en-Y gastric bypass (RYGB) surgery is an effec-tive long-term intervention for weight loss mainte-
nance in obesity (1). Whereas RYGB and other bariatric
surgeries reduce appetite, patients after RYGBalso have
reduced food reward responses (2–4). A reduction in
food preference or appetitive behaviors for energy-
dense sweet/fatty foods is reported after RYGB but not
laparoscopic adjustable gastric banding (BAND), in
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which an inflatable band is put around the proximal
stomach, or the similar vertical banded gastroplasty (2,
4–6). Appetitive reward for chocolate sweets but not
vegetables is reduced after RYGB as measured by the
effort expended to obtain food during a progressive
ratio task (PRT) (7). Behaviors seen in rodent RYGB
models are consistent with such clinical findings (2, 8).
The exact mechanisms behind these beneficial changes
in food reward remain unclear because RYGB combines
severalmanipulations, including the following: 1) reduced
gastric pouch size, 2) gastric vagus nervemanipulation, 3)
exclusion of food from the stomach and proximal small
bowel, 4) disrupted bile flow with increased plasma bile
acids, 5) altered gut microbiota, 6) aversive postprandial
effects (dumping syndrome), and 7) enhanced postpran-
dial plasma concentrations of satiety gut hormones in-
cluding peptide YY (PYY), glucagon-like peptide-1
(GLP-1) and fibroblast growth factor 19 (FGF19), related
to earlier delivery of food to themidgut and disrupted bile
flow (3, 4, 9–12). Postprandial plasma PYY and GLP-1
concentrations are substantially higher after RYGB than
BAND surgery (4, 13, 14).
We hypothesized that satiety gut hormones attenuate
appetitive and anticipatory food reward responses after
RYGB in humans and therefore that the acute suppression
of these hormones by sc administration of the somatosta-
tin analog octreotide would increase food reward in pa-
tients after RYGB.
In functional magnetic resonance imaging (fMRI)
studies, changes in blood oxygen level-dependent
(BOLD) signal reveal that activation in key brain re-
ward areas including amygdala, caudate, nucleus ac-
cumbens, anterior insula, and orbitofrontal cortex
(OFC) is lower after RYGB, when evaluating food pic-
tures, compared with BMI-matched patients after
BAND, despite both surgical groups having similarly
low hunger ratings (4). This lower anticipatory fMRI
reward response to food after RYGB was accompanied
by lower high-energy food picture appeal ratings (4).
Longitudinal reductions in high-energy food hedonics
and reward responses using fMRI have also been re-
ported after compared to before RYGB surgery (15).
Although PYY andGLP-1 additively increase satiety to
reduce caloric intake (16, 17), direct evidence for their
importance in the reduced food intake after RYGB re-
mains unproven. Antagonism of GLP-1 increases food in-
take and body weight after RYGB in rodents but no more
than in sham-operated animals (18), whereas genetic dis-
ruption of GLP-1 release or GLP-1 receptor (GLP-1R) in
rodent models of bariatric surgery does not attenuate
weight loss (18–20). Antagonism of PYY has not consis-
tently increased food intake and body weight in RYGB
rodent models (14, 18), but knockout of Pyy increased
food intakeandattenuatedweight loss afterRYGB inmice
(21). Nevertheless, a broader intervention through acute
suppression of several plasma gut hormones including
PYY and GLP-1 secretion by administration of the soma-
tostatin analog octreotide does increase food intake in
both rats (22) and humans (23) after RYGB. Chronic sc
administration of octreotide for dumping syndrome after
RYGB also leads to weight gain (24).
Additional roles for these satiety gut hormones have
recently been postulated for the changes in food reward
after RYGB (4). PYYmodulates resting activity in brain
reward systems (25), and PYY and GLP-1 are additive
in reducing BOLD signal in response to food pictures in
the amygdala, caudate, putamen, nucleus accumbens,
anterior insula, and OFC in nonobese subjects (17).
Furthermore, the reduction in brain responses to food
pictures with a GLP-1R agonist in nonobese and obese
subjects is blocked by coadministration of a GLP-1R
antagonist (26). In animal studies GLP-1R agonists re-
duce food intake and reward-based eating behavior, for
example, reducing the effort expended to obtain sucrose
in rats using a PRT, through the nucleus accumbens and
mesolimbic pathways (27).
Despite these observations, no mechanistic study has
yet directly establishedwhich specific anatomical or phys-
iological perturbation after RYGB in humans reduces
food reward. The objectives of this study included the
following: 1) investigate the effect of satiety gut hormone
suppression, using acute administration of octreotide, on
food hedonic-reward responses in subjects after RYGB,
using established behavioral and functional neuroimaging
methodologies, and2) compare these responseswith those
of subjects without enhanced postprandial gut hormone
secretion, namely obese unoperated controls or patients
after BAND surgery.
Metabolic and Molecular Imaging Group (A.P.G., A.D.M., S.S., N.C., J.D.B.), Robert Steiner MRI Unit (G.D.), Medical Research Council Clinical Sciences Centre, and Centre for
Neuropsychopharmacology (A.P.G.) and Computational, Cognitive, and Clinical Neuroimaging Laboratory (A.P.G., N.C.), Division of Brain Sciences, and Division of Diabetes, Endocri-
nology, and Metabolism (A.D.M., C.W.l.R.), Imperial College London, Hammersmith Hospital, LondonW12 0NN, United Kingdom; Diabetes Complications Research Centre (S.J., K.J.N.,
J.G., S.M., C.W.l.R.), Conway Institute, School of Medicine and Medical Science, University College Dublin, Belfield, Dublin 4, Ireland; Centre National de la Recherche Scientifique Unité
Mixte de Recherche 6265 (L.P., S.M.), Centre des Sciences du Goût et de l’Alimentation, and Institut National de la Recherche Agronomique Unité Mixte de Recherche 1324 (L.P., S.M.),
Centre des Sciences du Goût et de l’Alimentation, and Unité Mixte de Recherche Centre des Sciences du Goût et de l’Alimentation (L.P., S.M.), Université de Bourgogne, F-21000, Dijon,
France; ResearchCentre forOptimalHealth (J.D.B.),University ofWestminster, LondonW1W6UW,UnitedKingdom;andDepartmentofGastro Surgical ResearchandEducation (C.W.l.R.),
University of Gothenburg, 41345 Gothenburg, Sweden
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Eleven patients who had previously undergone RYGB sur-
gery were recruited from the obesity clinic at St Columcille’s
Hospital (Dublin, Ireland)with10unoperatednonobeseweight-
stable volunteers as age- and gender-matched controls. Inclusion
criterion for the RYGB group was surgery more than 5 months
previously. Exclusion criteria for both RYGB and control nono-
bese groupswere as follows: 1) smoking, 2) pregnancy or breast-
feeding, 3) significant neurological, psychiatric, or cardiovascu-
lar disease including addiction, stroke, and epilepsy other than
previous depression, 4) type 1 or 2 diabetes mellitus, 5) lack of
understanding of the test instructions, 6) dislike for the test stim-
uli, 7) active postoperative complications, and 8) current intol-
erance to sweet foods due to dumping syndrome.
Progressive ratio task visit protocol
Participants completed two 1.5-hour sessions at the Clinical
Research Centre (St Vincent University or St Columcille’s Hos-
pitals) in a within-subject, double-blind, randomized, crossover
design (Supplemental Figure 1A), using sequential list random-
ization. After an overnight 12-hour fast, participants were in-
jected sc with either 1 mL octreotide (Sandostatin, 100 g; No-
vartis Pharmaceuticals) or 0.9% saline (23) (Figure 1A). Water
was allowed during the overnight fast.
Five minutes after the injection, participants were asked to
consume an ad libitum breakfast of their choice until they felt
comfortably full to stimulate gut hormone release and achieve
similar degrees of satiety between groups. The quantity and
type of food eaten were recorded, and participants were given
the exact same at the second visit, which they all consumed.
One hour after breakfast, partici-
pants rated their hunger, fullness, de-
sire to eat, and nausea on a 10-cm
visual analog scale (VAS) (4) (Supple-
mental Table 1). Sixty-five minutes af-
ter breakfast, participants sat in front
of a computer screen with a plate of 20
chocolate sweets (M&M crispy can-
dies, 4 kcal each, energy: 43.7% sugars,
44.1% fat; Mars UK Ltd) and per-
formed the PRT (7). An increasing
number of computer mouse clicks is
needed to earn a sweet. The starting
ratio to get a reward was 10 clicks with
a geometric increment of 2 (ie, 10, 20,
40, etc) until the participant stopped
responding, which was the breakpoint.
No food or fluid was offered after the
task. Participant instructions are given
in the Supplemental Methods.
Blood sampling
After the completion of the PRT, 80
minutes after breakfast, venous blood
samples were collected for measurement
of serum insulin, plasma glucose, total
GLP-1, total PYY, and FGF19 (see Sup-
plemental Methods).
Functional magnetic resonance imaging study
Participants
Seven weight-stable patients who had previously undergone
RYGB surgery and nine weight-stable patients who had under-
gone BAND surgery, at the Imperial Weight Centre (Charing
Cross Hospital, London, United Kingdom) completed the fMRI
scanning as extra visits to a previous study (see Supplemental
Methods for further details) (4). Two additional new patients
after RYGB completed identical study visits performing the food
picture evaluation task outside the scanner because of contrain-
dications to MR scanning. Appeal ratings were therefore avail-
able for nine patients after RYGB, and fMRI scans for seven
patients after RYGB and nine patients after BAND surgery. Ex-
clusion/inclusion criteria were as described (4).
Scanning visit protocol
After an overnight fast (water was allowed), patients were
randomized, in a double-blind, crossover, within-subject design
(Figure 1B), to receive, 10 minutes before breakfast, either two
sc injections of 0.9% saline or octreotide (Sandostatin, 100 g;
Novartis Pharmaceuticals) (23) plus a short-acting insulin to
attenuate postprandial hyperglycemia from the suppression of
insulin (Actrapid, 0.075–0.10 U/kg; Novo Nordisk) as two sep-
arate injections. Subjects then received a standardizedmilkshake
breakfast (one sachet Complan plus 200 mL whole milk, giving
385 kcal; energy: carbohydrate 45.6%, fat 16.0%, protein
38.4%) at t 0minutes. Participants weremonitored for a total
of 165 minutes to ensure they did not become hypoglycemic.
Food picture evaluation fMRI paradigm
During the fMRI paradigm, starting at 95 minutes, four
types of color photographswere presented in a block design split
Figure 1. Study protocols. A, Progressive ratio task. B, Functional MRI food evaluation study.
Note that the PRT lasted 10 minutes and all participants finished the task within this time period.
The time interval between the end of the PRT and the 80-minute blood sample ranged from 9
to 13 minutes. AMV, auditory-motor-visual; BP, blood pressure; MRI, magnetic resonance
imaging.
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across two runs: 1) 60 high-energy foods (eg, pizza, cakes, and
chocolate); 2) 60 low-energy foods (eg, salads, vegetables, fish);
3) 60 nonfood-related household objects (eg, furniture, cloth-
ing), with each category in 10 blocks; and 4) 180 Gaussian
blurred images of the other pictures, as described (4, 28).
While each image was on display to subjects in the scanner,
they were asked to immediately and simultaneously rate how
appealing each picturewas to themusing a five-button handheld
keypad (1, not at all; 5, a lot) (4, 28).
Auditory-motor-visual control fMRI paradigm
In the 6-minute auditory-motor-visual (AMV) control task,
over nine blocks, subjects performed two of the following tasks
simultaneously: 1) listening to a story, 2) tapping their right
index finger once every second, or 3) watching a 4-Hz color
(yellow/blue) flashing checkerboard, with each task performed
in six blocks (4, 28). This control fMRI task was used to ensure
that changes in the BOLD signal were not nonspecific, eg, due to
alterations in neurovascular coupling.
fMRI analysis
Preprocessing used the fMRI Expert Analysis Tool version
5.98 software, part of the FMRIB Software Library, version 4.1
(www.fmrib.ox.ac.uk/fsl), as described (4, 28).
The average (median) BOLD signal for the contrast high-
energy foodgreater thanobject and low-energy foodgreater than
object were calculated for each subject at each visit in these func-
tional regions of interest (fROIs): amygdala, nucleus accumbens,
anterior insula, and caudate nucleus (4, 28). The fROIs were
determined from a separate cohort of 24 overweight/obese sub-
jects who underwent an identical protocol after fasting over-
night, without administration of octreotide/Insulin, for the food
(high energy or low energy) greater than object contrast at voxel-
wise false discovery rate corrected P  .05, as previously de-
scribed (4) (and see SupplementalMethods). Excess signal drop-
out precluded the use of an OFC fROI. Similar functional
localizers were made for the control AMV task for bilateral su-
perior posterior temporal gyrus (auditory), left precentral gyrus
(motor), and bilateral lingual gyrus (visual) from the same sep-
arate cohort of 24 overweight/obese subjects, as described (4).
Appetite ratings
VAS ratings (0–10 cm) of appetite and other symptoms were
recorded at serial time points tomeasure hunger, pleasantness to
eat, volume of foodwanting to eat, fullness, and sickness (4, 28).
Blood sampling
The concentration of serum insulin, plasma glucose, insulin
and totalGLP-1, total PYY,andFGF19 (see SupplementalMeth-
ods for assay methods) over the scanning period was calculated
using themeanof concentrations at time point70minutes (just
before the fMRI scan) and time point 150 minutes (just after
the fMRI scan).
Statistical analysis
SPSS version 21 (IBM) and Prism version 5 (GraphPad Soft-
ware Inc) were used to perform the statistical analyses. Results
are presented asmean SEMormedian [interquartile range] for
data that was not normally distributed (Kolmogorov-Smirnov
test) and range. Significancewas taken asP .05. Effect sizes are
described as mean difference SEM, 95% confidence intervals
(CI), and Cohen’s d values.
Between-group comparisons used an unpaired Student’s t
test, Mann-Whitney U test (if data not normally distributed),
or Fisher’s exact test for categorical variables to examine
group differences. Within-group comparisons used a paired t
test or Wilcoxon rank sum test (if data were not normally
distributed) to examine the response to treatment (octreotide
vs saline) separately in each group. In the fMRI study, a two-
Table 1. Participant Characteristics in Progressive Ratio Task and fMRI Food Evaluation Studies
Progressive Ratio Task Study fMRI Food Evaluation Studya
Controls RYGB
P
Valueb RYGB (All) RYGB (Scanned)c BAND
P
Valued
n 10 11 9 7 9
Age, y 45.3  3.4 (31.0, 62.0) 50.5  9.2 (34.0, 68.0) .25 47.0  1.8 (42.0, 59.0) 46.0  1.0 (42.0, 50.0) 41.8  3.8 (26.0, 59.0) .22
Gender (male/female) 6/4 6/5 1.00 3/6 2/5 1/8 .58
European Caucasians, n, % 10 (100%) 11 (100%) 1.00 9 (100%) 7 (100%) 6 (75%) .21
Preoperative BMI, kg/m2 n/a 54.0  2.8 (41.2, 71.0) n/a 52.8  2.0 (38.3, 74.6) 55.2  5.3 (38.3, 74.6) 51.7  4.8 (36.5, 86.2) .84
Current BMI, kg/m2 24.5  0.6 (20.6, 26.9) 38.8  2.0 (25.8, 49.1) .02 37.3  2.6 (29.4, 48.8) 38.6  3.1 (29.4, 48.8) 33.2  6.3 (25.2, 43.8) .25
Current weight, kg 71.8  3.2 (56.1, 88.20) 110.6  8.9 (63.5, 169.9) <.001 105.6  6.2 (75.0, 129.3) 109.0  6.4 (82.2, 129.3) 91.3  4.8 (75.5, 115.1) .10
Current body fat, % ND ND n/a 42.0  3.9 (23.1, 55.1) 41.5  5.0 (23.1, 55.1) 40.2  3.2 (23.6, 52.0) .73
Weight loss, % preoperative
weight
n/a 27.2  3.9 (3.0, 47.0) n/a 28.3  2.0 (21.1, 38.3) 29.1  2.4 (21.1, 38.3) 27.4  4.0 (10.0, 52.0) .84
Time since surgery, mo n/a 28.4  5.5 (5.6, 68.0) n/a 15.6  2.5 (5.2, 23.9) 14.2  3.0 (5.2, 23.9) 15.3  3.6 (4.0, 36.0) .95
Preoperative DM, n, % n/a 2 (18%) n/a 5 (56%) 4 (57%) 0 (0%) .03
Current DM, n, % 0 (0%) 1 (9%) 1.00 1 (11%) 1 (14%) 0 (0%) 1.00
Preoperative BED, n, % n/a ND n/a 2 (22%) 1 (14%) 2 (22%) 1.00
Current BED, n, % ND ND n/a 1 (11%) 1 (14%) 0 (0%) 1.00
Abbreviations: BED, binge eating disorder; BMI, body mass index; DM, type 2 diabetes mellitus; n/a, not applicable; ND, not determined. Data are
presented as mean  SEM and (minimum, maximum), or n (percentage). Bold text indicates P  .05.
a Data are calculated from the average of the two visits in the fMRI evaluation study.
b P value for comparison of controls vs RYGB, using independent two-tailed t test for continuous variables or Fisher’s exact test for prevalence
data.
c Excluding two participants with contraindications to MRI.
d P value for comparison of RYGB (all) vs BAND, using independent two-tailed t test for continuous variables or Fisher’s exact test for prevalence data.
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way, repeated-measures ANOVA including treatment (oc-
treotide vs saline) and food picture energy density (high energy
vs low energy food) as within-subject factors was used to
determine the effects of treatment, energy density, and treat-
ment energy density interaction, sep-
arately within each group, with post
hoc Fisher’s least significance differ-
ence (LSD) test. Amultivariate analysis
was performed using all fROIs as well
as a univariate analysis for each indi-
vidual fROI or an average signal across
all fROIs.
To directly compare the effects of oc-
treotide between groups, univariate,
two-way, repeated-measures ANOVAs
were performed including treatment (oc-
treotide vs saline) as within-subject fac-
tor and group as between-subject factor
to determine effects of treatment, group,
and treatment group interaction, with
a post hoc Fisher’s LSD test. In the fMRI
analyses, energy density (high energy vs
low energy food) was also included as an
additional within-subject factor in a uni-
variate, three-way, repeated-measures
ANOVA. Given our a priori hypothesis
of enhanced effects of octreotide in the
RYGB groups, we illustrate the post hoc
effects of treatment within each group,
irrespective of the treatment group in-
teraction effect.
Pearson correlation coefficients r
were determined from linear regression
analysis to examine the relationship be-
tween the change in outcome variables
between octreotide and saline visits and
either the variable at the saline visit or the
change in plasma gut hormones between
the octreotide and saline visits.
Results
Progressive ratio task
The healthy nonobese control
group and adults after RYGB were
of similar age, gender ratio, and
ethnicity, but the RYGB group re-
mained significantly heavier than
controls (Table 1). Five of the 10
controls and five of the 11 RYGB
subjects had the saline injection at
the first visit.
Glucose and hormone responses
As expected, compared with sa-
line administration, octreotide sup-
pressed postprandial plasma PYY
and GLP-1, and serum insulin, but
also plasma FGF19, concentrations in patients after
RYGB (Figure 2, B–E, and Supplemental Table 2). In con-
trols this suppressive effect of octreotide was significant
Figure 2. Octreotide suppressed postprandial plasma gut hormones in progressive ratio task. A,
Plasma glucose. Octreotide significantly increased plasma glucose in patients after RYGB (mean
difference [95% CI] 0.6 [0.2, 1.1] mmol/L, F[1, 19] 7.84, P .011, Cohen’s d 0.84) but not in
controls (0.3 [0.2, 0.8] mmol/L, F[1, 19] 1.25, P .28, Cohen’s d 0.00). To convert millimoles
per liter to milligrams per deciliter, multiply by 18.01. B, Serum insulin. Octreotide significantly
decreased serum insulin in patients after RYGB (mean difference [95% CI]22.3 [27.7,16.9]
mU/L, F[1, 19] 74.88, P .001, Cohen’s d 2.05) but not in controls (4.0 [9.6, 1.7] mU/L, F[1,
19] 2.15, P .10, Cohen’s d 1.08). To convert milliunits per liter to picomoles per liter, multiply
by 7.175. C, Plasma GLP-1. Octreotide significantly decreased plasma total GLP-1 both in patients
after RYGB (mean difference [95% CI]18.7 [27.7,9.6] pmol/L, F[1, 18] 18.81, P .001,
Cohen’s d 0.98) and in controls (11.0 [20.0,1.93] pmol/L, F[1, 8] 6.50, P .020, Cohen’s
d 1.49). D, Plasma PYY. Octreotide significantly decreased plasma total PYY in patients after RYGB
(mean difference [95% CI]143.8 [193.3,94.4] pg/mL, F[1, 19] 37.08, P .001, Cohen’s
d 1.48) but not in controls (30.0 [81.8, 21.9] pg/mL, F[1, 19] 1.46, P .24, Cohen’s d
0.62). To convert picograms per milliliter to picomoles per liter, multiply by 0.25. E, Plasma FGF19.
Octreotide significantly decreased plasma FGF19 in patients after RYGB (mean difference [95% CI]
36.6 [59.4,13.7] pg/mL, F[1, 19] 11.23, P .003, Cohen’s d 0.91) but not in controls
(12.1 [36.1, 11.9] pg/mL, F[1, 19] 1.12, P .30, Cohen’s d 0.47). Data represent mean
SEM (n 11 per group except RYGB group, GLP-1, n 10). White bars, saline; black bars,
octreotide. *, P .05, ***, P .001 with post hoc Fisher’s LSD test. For statistics of repeated-
measures ANOVA for effects of group, treatment, and group treatment interaction, see
Supplemental Table 2.
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only forGLP-1.However, therewas a significantly greater
suppression of insulin and PYYwith octreotide in patients
after RYGB than controls but not for GLP-1 or FGF19
(Figure 2, B and D, and Supplemental Table 2).
Octreotide significantly increased postprandial plasma
glucose in patients after RYGB but not controls, although
concentrations remained at 7.7 mmol/L or less (139 mg/
dL), ie, not in the hyperglycemic range, and there was no
significant difference between groups in the effect of oc-
treotide on plasma glucose (Figure 2A and Supplemental
Table 2).
At the saline visit, postprandial serum insulin and plasma
PYY concentrations were greater in patients after RYGB
than nonobese control subjects (insulin: mean difference
RYGB minus control [95% CI] 19.0 [11.4, 26.7] mU/L,
F[1, 19] 27.41, P .001, Cohen’s d 2.29; PYY: 128.0
[56.6, 199.3] pmol/L, F[1, 19] 14.08, P .001, Cohen’s
d  1.64), with a similar trend for plasma FGF19 (28.0
[3.2, 59.2] pg/mL, F[1, 19]3.54,P .075,Cohen’s d
0.82)(Figure2andSupplementalTable2).However,plasma
glucose andGLP-1 concentrationswerenot significantlydif-
ferent between groups (glucose: 0.4 [1.0, 0.2] mmol/L,
F[1, 19]  2.39, P  .14, Cohen’s d  0.68; GLP-1: 19.8
[3.8, 23.3] pmol/L, F[1, 18] 2.28, P .15, Cohen’s d
0.67) (Figure 2 and Supplemental Table 2).
Behavioral responses
The breakpoint of the PRT, which represents the
amount of work the subject did to obtain the reward, was
not significantly different between RYGB and control
groups after saline administration (Figure 3 and Supple-
mental Figure 1).Therewas a significantly greater effect of
octreotide in the RYGB comparedwith the control group,
with octreotide significantly increasing the breakpoint in
patients after RYGB (Figure 3 and Supplemental Figure 1)
but not the control group. By contrast, octreotide had no
significant effects on the VAS ratings of hunger, fullness,
or nausea in either group (Supplemental Table 1).
Hormone-behavior correlations
There was no significant correlation between the in-
crease in PRT breakpoint, and the decrease in plasma
PYY, GLP-1, or FGF19, with octreotide administration
(bothoctreotide-saline) in patients after RYGB alone, or
in the RYGB and control group combined (Supplemental
Table 3).
fMRI study
Appeal ratings were available for nine RYGB subjects
and fMRI scans for seven RYGB subjects. The RYGB and
BAND groups were of similar age, gender ratio, ethnicity,
preoperative BMI, current BMI, and percentage body fat,
percentage weight loss since surgery, and time since sur-
gery (Table 1).
Glucose and hormone responses
At the saline visit, postprandial serum insulin and, as
expected, theplasmaGLP-1andPYYconcentrationswere
significantly greater in patients after RYGB than after
BAND (insulin: mean difference RYGB minus BAND
[95%CI] 5.7 [1.2, 10.3]mU/L, F[1, 16] 7.07,P .017,
Cohen’s d  1.25; GLP-1: 12.3 [2.6, 22.0] pmol/L, F[1,
16]7.26,P .016,Cohen’sd1.27;PYY:123.4 [12.6,
234.1] pg/mL, F[1, 16]  5.58, P  .031, Cohen’s d 
1.11) (Figure 4 and Supplemental Table 2). However,
there was no significant difference in plasma glucose or
FGF19 concentrations between the RYGB and BAND
groups (glucose: 0.2 [1.2, 0.8] mmol/L, F[1, 16] 
0.27, P  .61, Cohen’s d  0.25; FGF19: 31.0 [20.9,
83.0] pg/mL, F[1, 16] 1.60, P .22, Cohen’s d 0.60)
(Figure 4 and Supplemental Table 2).
As expected, the gut hormone-suppressive effects of
octreotide in the RYGB group were similar in the fMRI
study to that in the PRT study. Compared with the saline
administration, octreotide significantly suppressed post-
prandial plasma GLP-1, PYY, and again FGF19 over the
scanning period (Figure 4, C–E). Interestingly, octreotide
also suppressed postprandial GLP-1 and PYY but not
postprandial FGF19 in the BAND group (Figure 4, C–E).
Octreotide had a greater suppressive effect on plasma
GLP-1 and PYY in the RYGB group than the BAND
group, with a similar trend seen for FGF19 (Supplemental
Table 4). This appears to be a consequence of higher post-
prandial plasmagut hormone concentrations, particularly
Figure 3. Octreotide increased food reward responses in progressive
ratio task. Octreotide significantly increased the total number of clicks
(breakpoint) in patients after RYGB (mean difference [95% CI] 503
[218, 788], F[1, 19]  13.66, P  .002, Cohen’s d  0.62) but not in
controls (effect size 1 [300, 298], F[1, 19]0.00, P  .99, Cohen’s
d  0.00). Overall ANOVA: group (between subject), F(1, 19)  1.53,
P  .23; treatment (within subject), F(1, 19)  6.47 P  .02; group 
treatment interaction, F(1, 19)  6.54, P  .02.
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for GLP-1, in patients after RYGB
than BAND at the saline visit.
The coadministration of exoge-
nous insulin avoided the potential
confoundof significantly lowerpost-
prandial serum insulin concentra-
tions after octreotide in both the
RYGB and BAND groups (Figure
4B). In the BAND group, coadmin-
istration of octreotide and exoge-
nous insulin did not increase
postprandial glucose concentrations
(Figure 4A). However, postprandial
glucose concentrations still in-
creased after octreotide in the RYGB
group, although the concentrations
were 9.5 mmol/L or less (171 mg/
dL) (Figure 4A and Supplemental
Table 4). None of our patients re-
ported any hypoglycemic adverse
events after discharge from the clin-
ical research facility.
Food hedonic responses
Compared with saline, octreotide
significantly increased the food ap-
peal ratings in patients after RYGB
(Figure 5A) but not in patients after
BAND (Figure 5B). However, on di-
rect comparison, therewas no signif-
icant difference in the effect of oc-
treotide on food appeal ratings
between the surgical groups (Supple-
mental Figure 2A and Supplemental
Table 5).
BOLD signal responses
In the RYGB group, multivariate
analysis including all the a priori
fROIs (nucleus accumbens, caudate,
anterior insula, amygdala) revealed
that octreotide significantly increased
theBOLDsignalduringtheevaluation
of food pictures (F[4, 3] 13.86, P
.028), independent of the food picture
energydensity (energydensity treat-
ment interaction [F[4, 3] 0.57, P
.71]). Inunivariateanalysesof individ-
ual fROIs in the RYGB group, oc-
treotide significantly increased the
BOLD signal during the food picture
evaluation averaged across all the a
priori fROIs and in the nucleus ac-
Figure 4. Octreotide suppressed postprandial plasma gut hormones in fMRI food evaluation
study. A, Plasma glucose. Octreotide significantly increased plasma glucose in patients after
RYGB (mean difference [95% CI] 2.2 [0.9, 3.5] mmol/L, F[1, 16]  12.78, P  .003, Cohen’s d 
2.31) but not in patients after BAND (0.5 [0.8, 1.8] mmol/L, F[1, 16]  0.55, P  .47, Cohen’s
d  0.48). To convert millimoles per liter to milligrams per deciliter, multiply by 18.01. B, Serum
insulin. Octreotide did not have a significant effect on serum insulin in patients after RYGB (mean
difference [95% CI] 1.6 [5.1, 1.9] mU/L, F[1, 16]  0.94, P  .35, Cohen’s d  0.26) or in
patients after BAND (0.2 [3.7, 3.3] mU/L, F[1, 16]  0.01, P  .92, Cohen’s d  0.11). To
convert milliunits per liter to picomoles per liter, multiply by 7.175. C, Plasma GLP-1. Octreotide
significantly decreased plasma total GLP-1 in patients after RYGB (mean difference [95% CI]
22.6 [27.3, 17.8] pmol/L, F[1, 16]  102.16, P  .001, Cohen’s d  1.80), with a
significantly smaller decrease in patients after BAND (10.4 [15.1, 5.7] pmol/L, F[1, 16] 
21.74, P  .001, Cohen’s d  1.90). D, Plasma PYY. Octreotide significantly decreased plasma
total PYY in patients after RYGB (mean difference [95% CI] 146.8 [203.5, 90.1] pg/mL, F[1,
16]  30.12, P  .001, Cohen’s d  0.95), with a significantly smaller decrease in patients after
BAND (57.6 [114.3, 0.88] pg/mL, F[1, 16]  4.63, P  .047, Cohen’s d  1.95). To convert
picograms per milliliter to picomoles liter, multiply by 0.25. E, Plasma FGF19. Octreotide
significantly decreased plasma FGF19 in patients after RYGB (mean difference [95% CI] 28.5
[50.4, 6.5] pg/mL, F[1, 16]  7.54, P  .014, Cohen’s d  0.40) but not in patients after
BAND (12.1 [36.1, 11.9] pg/mL, F[1, 16]  0.02, P  .90, Cohen’s d  0.08). Data represent
mean  SEM (n  9 per group). White bars, saline; black bars, octreotide. *, P  .05, ***, P 
.001 with post hoc Fisher’s LSD test. For statistics of repeated-measures ANOVA for effects of
group, treatment, and interaction, see Supplemental Table 4.
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cumbens alone (Figure 5, C and E). Interestingly a lower
food appeal and BOLD signal during food evaluation
after saline was associated with a greater increase in
these variables with octreotide administration (Supple-
mental Figure 3).
By contrast, in a multivariate
analysis of all fROIs in the BAND
group, octreotide had no significant
effect on BOLD signal during evalu-
ation of food pictures in the a priori
fROIs: (F[4, 5] 0.45, P .77), in-
dependent of the food picture energy
density (energy density  treatment
interaction [F[4, 5]  0.26, P 
.89]). Similarly in univariate analy-
ses of individual fROIs in the BAND
group, octreotide had no significant
effect on BOLD signal during food
picture evaluation averaged across
all the a priori ROIs or in the nucleus
accumbens (Figure 5, D and F).
However, on direct comparison,
there was no significant difference in
the effect of octreotide on BOLD sig-
nal averaged across all four a priori
fROIs, the nucleus accumbens, or
other individual ROIs (Supplemental
Figure 2 and Supplemental Table 5).
Hormone-BOLD signal
correlations
In the combined surgical group
analysis (n 16), there was a signif-
icant positive correlation between
the increase in the BOLD signal to
the food pictures averaged across the
a priori fROIs with octreotide ad-
ministration and the decrease in
plasma PYY with octreotide admin-
istration (r[15]  0.56, P  .02,
Figure 6A), with a similar trend for
GLP-1 (r [15]0.45,P .08, Fig-
ure 6B), but not FGF19 (r[15] 
0.06, P  .83).
Confounding variables
Aswith the PRT study, octreotide
had no significant effects in either
the RYGB or BAND groups on the
following: 1) VAS ratings of hunger
or fullness (Supplemental Tables 6
and 7), 2) BOLD signal during
the control auditory-motor-visual
fMRI task (suggesting a lack of nonspecific effects), 3)
motion during scanning, 4) emotional ratings (Supple-
mental Tables 8 and 9), or 5) postprandial signs and
symptoms of the dumping syndrome (Supplemental Ta-
bles 10 and 11).
Figure 5. Effect of octreotide on hedonic and brain reward system responses in fMRI food
evaluation task after RYGB and BAND. A and B, Octreotide increased food appeal ratings in
patients after RYGB (mean difference [95% CI] 0.35 [0.01, 0.70], F[1, 8]  5.48, P  .047,
Cohen’s d  0.43) (A) but not BAND (mean difference [95% CI] 0.049 [0.38, 0.48], F[1, 8] 
0.07, P  .80, Cohen’s d  0.07) (B). C and D, Octreotide significantly increased average BOLD
signal (percentage) to any food picture averaged across all four fROIs (nucleus accumbens,
caudate, anterior insula, amygdala) in patients after RYGB (mean difference [95% CI] 0.062
[0.003, 0.122], F[1, 6]  6.54, P  .043, Cohen’s d  0.77) (C) but not BAND (mean difference
[95% CI] 0.047 [0.051, 0.146], F[1, 8]  1.21, P  .30, Cohen’s d  0.68) (D). E and F,
Octreotide significantly increased average BOLD signal (percentage) to any food picture in the
nucleus accumbens alone in patients after RYGB (0.102 [0.023, 0.180], F[1, 6]  10.11, P 
.019, Cohen’s d  0.79) (E) but not BAND (mean difference [95% CI] 0.069 [0.037, 0.174],
F[1, 8]  2.27, P  .17, Cohen’s d  0.82) (F). Analysis from repeated-measures ANOVA
performed separately in each group, RYGB (n  7, except food appeal rating, n  9) or BAND
(n  9), with treatment (octreotide or saline) and energy density of food pictures (high or low) as
within-subject factors. There was no significant effect of food picture energy density or energy
density  treatment interaction for any fROI in either group. *, P  .05, octreotide vs saline with
post hoc Fisher’s LSD test. For statistics of repeated-measures ANOVA for effects of group,
treatment, and interaction, see Supplemental Table 5.
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Discussion
In two cohorts of patients after RYGB using complimen-
tary behavioral tests and functional neuroimaging, we
demonstrate that lowering postprandial plasma satiety
gut hormones by acute octreotide administration in-
creased the breakpoint for a chocolate sweet in a PRT and
increased food appeal ratings and brain reward system
activation during evaluation of food pictures.
These measures of food reward are of direct relevance
to actual habitual eating behavior, food intake, and
changes in body weight, although these are not examined
in the current study. The magnitude of change in the
breakpoint for chocolate sweets in the PRT have been
correlated with the degree of weight loss after RYGB (7),
and the breakpoint for different foods correlate with ha-
bitual dietary intake and energy intake in test meals (29).
The BOLD signal in brain reward regions, including the
nucleus accumbens, caudate, amygdala, and insula, to
anticipatory food cues correlate with pleasantness rat-
ings of ingested food after bariatric surgery (4), and
predict food intake at test meals (30, 31) andweight loss
during lifestyle modification (32). The caudate and nu-
cleus accumbens are involved in habitual and goal- and
reward-directed behavior. The anterior insula incorpo-
rates the primary taste cortex and together with the
amygdala, which predominantly responds to emotions
but also receives gustatory and other multimodal sen-
sory inputs, form part of a brain network that regulates
stimulus-response association and motivation to re-
wards such as food.
By suppressing postprandial re-
lease of gut hormones such as GLP-1
and PYY, octreotide administration
has anadvantageover specific antag-
onists in attenuating the additive ef-
fects of several satiety gut hormones
to reduce reward-related eating be-
havior (17). A novel finding in both
our studies was that octreotide re-
duced elevated postprandial plasma
FGF19 in patients after RYGB. This
could be via a direct effect on soma-
tostatin receptors on enterocytes or
perhapsmediated indirectly through
changes in other gut hormone path-
ways. FGF19 has a central anorexi-
genic action in rodents (33) in addi-
tion to roles in regulation of liver,
lipid, and glucose metabolism (34).
Indeed, weight loss after vertical
sleeve gastrectomy in rodents is de-
pendent on intact signaling at the
farsenoid-X receptor that mediates the stimulation of
FGF19 secretion by enterocytes in response to bile acids
(13). In our fMRI study, although increased reward sys-
tem BOLD signal with octreotide correlated with the sup-
pressionof PYY in the combinedbariatric surgical groups,
with a similar trend for GLP-1, this was not seen for
FGF19, suggesting amore prominent role for PYY/GLP-1
in mediating these changes. Nevertheless, a potential role
for FGF19 in reward-related eating behavior would be
worthy of further study.
Whereas octreotide-induced hypoinsulinemia could
contribute to the increased breakpoint in the PRT study
and enhanced food reward (35–37), increases in hedonic-
brain responses to food in the fMRI study were still seen
despite its prevention by coadministration of exogenous
insulin. However, this is a potential limitation in the in-
terpretation of the PRT study. Furthermore, the relative
hyperglycemia seen after octreotide in both studieswould,
if anything, be expected to attenuate rather than enhance
such reward responses (38, 39).
Activation of brain somatostatin 2 receptors stimulates
feeding in rodents, raising the possibility of a direct brain
effect of octreotide (40). However, the increase in PRT
breakpoint for the sweet chocolate rewardwith octreotide
in the RYGB group was not seen in the control nonobese
group, suggesting a lack of nonspecific or direct central
effects of the somatostatin analog. Similarly, the increase
in food appeal and reward system BOLD signal with oc-
treotide in the RYGB group was not seen in the matched
BANDgroup.However, no significant differencewas seen
Figure 6. Greater suppression of plasma PYY and GLP-1 with octreotide is associated with
greater increase in brain reward system response in fMRI food evaluation task after bariatric
surgery. The magnitude of the increase in BOLD signal (percentage) averaged across the four
fROIs (nucleus accumbens, caudate, anterior insula, amygdala) to any food picture (high energy
or low energy vs objects) with octreotide (delta octreotide-saline) was positively correlated with
the decrease in plasma concentration of PYY with octreotide (delta saline-octreotide) (A), with a
similar trend for plasma concentrations of GLP-1 (B), independent of the surgical group. r
represents Pearson correlation coefficient. Open circles represent patients after BAND (n  9)
and filled circles patients after RYGB (n  7). Results for PYY are displayed as log10 scale because
data were not normally distributed. One RYGB subject with a decrease in plasma PYY after
octreotide of 401.3 pg/mL was an outlier (	 2 SD) in these analyses. The relationship between
delta BOLD signal and delta plasma PYY remained significant when excluding this subject (r[14]
 0.54, P  .036).
doi: 10.1210/jc.2015-2665 press.endocrine.org/journal/jcem 607
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 11 August 2016. at 03:29 For personal use only. No other uses without permission. . All rights reserved.
between the response to octreotide in direct comparisons
between the RYGB and BAND groups. This is likely re-
lated to the small number of subjects studied and stringent
statistics used but also due to the fact that octreotide does
still have an effect to reduce postprandial PYY andGLP-1
secretion in patients after BAND.The attenuation of these
satiety gut hormones with octreotide was lower in the
BAND than RYGB groups, related to higher postprandial
concentrations afterRYGB.Togetherwith the correlation
results in the combined surgical groups, these findings sug-
gest that gut hormones may have a concentration-depen-
dent attenuating effect on the reward systemBOLD signal
after bariatric surgery.
A limitation of our study is the small number and
power, especially in the exploratory fMRI study, meaning
that the findings are in need of confirmation in larger stud-
ies. This may also have resulted in false-positive as well as
false-negative errors, for example, in the analysis of the
interaction with food energy density and lack of signifi-
cance in the BAND group in the fMRI study. However,
n  9 in the BAND group had a power of 0.74–0.88 to
detect similar differences in the BOLD signal with oc-
treotide as seen in the RYGB group (see Supplemental
Methods). Furthermore, we found a similar direction of
effect of octreotide to increase food reward using three
different measures (PRT breakpoint, food appeal, and
BOLD signal in brain reward system during food evalu-
ation) in two separate cohorts of patients after RYGB.We
did not include an unoperated obese control group in ei-
ther study, which would also have been of interest, par-
ticularly for the PRT study inwhich obesitymay influence
the breakpoint (7). However, the use of a BAND control
group in the fMRI study, as an extension of our previous
study (4), matched for BMI and weight loss, provided an
ideal control for weight loss from a surgical intervention
butwithout an exaggerated satiety gut hormone response.
Additionally, our study investigated only the acute but not
the chronic effects of satiety gut hormone suppression on
food reward, and therefore, firm conclusions on their role
in food intake and choice and long-term weight loss can-
not be made.
In conclusion, acute suppression of the enhanced post-
prandial responses of satiety plasma gut hormones, such
as PYY, GLP-1, and FGF19, increased both appetitive
food reward in a PRT, and brain-hedonic responses to
anticipatory food reward using fMRI, after RYGB. These
results are consistent with the hypothesis that enhanced
satiety gut hormone responses after RYGB, resulting from
anatomical alteration of the upper gastrointestinal tract,
contribute to the reduction in brain-hedonic responses to
food after RYGB. This gives new insights into the increas-
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